Check out your Company Bowl for anonymous work chats.
During the 36th Annual JPMorgan Healthcare Conference, Exact Sciences CFO Jeff Elliott highlighted how the company will “continue to invest in our team, facilities, and infrastructure to support the company’s long-term growth”
Check out the new Exact Sciences Careers page.
Exact Sciences continued growth is fueled by strong demand for Cologuard during the fourth quarter. We pre-announced Q4 2017 earnings ahead of the JPMorgan Healthcare Conference, highlighting that revenue increased 168% and approximately 571,000 people were screened for colorectal cancer last year using our accurate, non-invasive option.
People of color and women hold a small fraction of jobs in science and engineering. Find out what Exact Sciences and Urban league are doing to change that.
Exact Sciences' Chief Medical Officer, Barry Berger, discusses the National Colorectal Cancer Roundtable’s 80% by 2018 pledge and how Cologuard is making an impact.
Exact Sciences earns a place in Deloitte's Technology Fast 500. The annual list ranks the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors.
Cologuard is not just a colorectal cancer screening test. Exact Sciences Laboratories utilizes a patient compliance program to help patients understand the test, feel supported, and follow through with their screening. For individuals 50 and above, at average risk for colon cancer.
Exact Sciences released 3rd quarter earnings. Hear from CFO Jeff Elliott.
Breaking news - we’re breaking ground! The west side of Madison, WI is the new site for our additional laboratory. We are excited to continue growing our business, expanding employment opportunities and contributing to the local community.
#TeamCologuard tells the stories of the team members who work behind-the-scenes to complete your Cologuard test after it's prescribed. Meet the people who are helping you get screened for colon cancer.
